EBITDA for Biogen (BIIB)
According to Biogen's latest reported financial statements, the company's current EBITDA (TTM) is $3.10B USD. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
BIIB
Currently viewingEBITDASwitch metric
TTM (last 4 quarters)
$3.10B
YoY change
+3.5%
5Y CAGR
-9.5%
Peak year (2019)
$7.74B
Cumulative EBITDA
$75.99B
EBITDA history chart for Biogen (BIIB) from 1985 to 2025
EBITDA history table for Biogen (BIIB) from 1985 to 2025
| Fiscal year | Period ended | Reported | EBITDA | YoY |
|---|---|---|---|---|
| 2025 | $3.10B | +3.5% | ||
| 2024 | $3.00B | +26.0% | ||
| 2023 | $2.38B | -32.8% | ||
| 2022 | $3.54B | -9.9% | ||
| 2021 | $3.92B | -23.2% | ||
| 2020 | $5.11B | -34.0% | ||
| 2019 | $7.74B | +10.3% | ||
| 2018 | $7.01B | +6.2% | ||
| 2017 | $6.61B | +4.1% | ||
| 2016 | $6.35B | +13.0% | ||
| 2015 | $5.62B | +21.9% | ||
| 2014 | $4.60B | +52.4% | ||
| 2013 | $3.02B | +37.1% | ||
| 2012 | $2.20B | +4.8% | ||
| 2011 | $2.10B | +29.7% | ||
| 2010 | $1.62B | -9.7% | ||
| 2009 | $1.80B | +7.6% | ||
| 2008 | $1.67B | +25.4% | ||
| 2007 | $1.33B | +53.2% | ||
| 2006 | $868.93M | +30.1% | ||
| 2005 | $668.05M | +27.9% | ||
| 2004 | $522.43M | -165.0% | ||
| 2003 | -$804.13M | -412.0% | ||
| 2002 | $257.75M | -40.1% | ||
| 2001 | $430.47M | -18.8% | ||
| 2000 | $530.45M | +52.7% | ||
| 1999 | $347.35M | +61.4% | ||
| 1998 | $215.23M | +27.9% | ||
| 1997 | $168.26M | +200.0% | ||
| 1996 | $56.09M | +205.5% | ||
| 1995 | $18.36M | +198.6% | ||
| 1994 | $6.15M | -78.3% | ||
| 1993 | $28.40M | -20.4% | ||
| 1992 | $35.70M | +839.5% | ||
| 1991 | $3.80M | -17.4% | ||
| 1990 | $4.60M | -180.7% | ||
| 1989 | -$5.70M | -35.2% | ||
| 1988 | -$8.80M | -56.9% | ||
| 1987 | -$20.40M | -18.4% | ||
| 1986 | -$25.00M | -12.0% | ||
| 1985 | -$28.40M | — |
EBITDA values are taken from Biogen's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
2025's annual EBITDA for Biogen (BIIB) came in at $3.10B – edged up 3.5% year-over-year.
Across 2020–2025 (5 years), Biogen EBITDA produced a CAGR of -9.5% – sustaining 2 straight years of year-over-year growth.
Biogen EBITDA plunged from $7.74B in 2019 to $3.10B in 2025, a 59.9% drawdown.
The highest annual EBITDA of $7.74B was reported in 2019. The lowest in the available history was -$804.13M in 2003.
Biogen (BIIB) sits 9th of 8 Healthcare peers we track on this metric, against a peer median of $24.21B.
Biogen EBITDA by Year
Biogen EBITDA 2025: $3.10B
Biogen EBITDA in 2025 was $3.10B, edged up 3.5% from 2024.
Biogen EBITDA 2024: $3.00B
Biogen EBITDA in 2024 was $3.00B, grew 26.0% from 2023.
Biogen EBITDA 2023: $2.38B
Biogen EBITDA in 2023 was $2.38B, plunged 32.8% below 2022.
Biogen EBITDA 2022: $3.54B
Biogen EBITDA in 2022 was $3.54B, declined 9.9% below 2021.
Biogen EBITDA 2021: $3.92B
Biogen EBITDA in 2021 was $3.92B.
See more financial history for Biogen (BIIB).
Sector peers — EBITDA
Companies in the same sector as Biogen, ranked by their latest EBITDA.
| Company | EBITDA | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $156.73B | Healthcare |
| Johnson & Johnson (JNJ) | $41.05B | Healthcare |
| Eli Lilly and Company (LLY) | $27.94B | Healthcare |
| Merck & Co., Inc. (MRK) | $25.36B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $23.06B | Healthcare |
| AstraZeneca PLC (AZN) | $19.83B | Healthcare |
| AbbVie Inc. (ABBV) | $17.63B | Healthcare |
| Amgen Inc. (AMGN) | $15.84B | Healthcare |
Frequently asked questions
What is Biogen's EBITDA?
- Latest reported EBITDA for Biogen (BIIB) is $3.10B (period ending December 31, 2025).
How has Biogen EBITDA changed year-over-year?
- Biogen (BIIB) EBITDA changed +3.5% year-over-year on the latest annual filing.
What is the long-term growth rate of Biogen EBITDA?
- Biogen (BIIB) EBITDA compound annual growth rate is -9.5% over the most recent 5 years available.
When did Biogen EBITDA hit its highest annual value?
- Biogen EBITDA reached its highest annual value of $7.74B in 2019.
What was Biogen EBITDA in 2024?
- Biogen (BIIB) EBITDA in 2024 was $3.00B.
What was Biogen EBITDA in 2025?
- Biogen (BIIB) EBITDA in 2025 was $3.10B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
BIIB Overview
Company profile, financial tools, and key metrics
BIIB Revenue Counter
Earns $311.09 every second. See per minute, hour, and day.
BIIB Earnings Counter
Earns $41.01 per second net profit. See per minute, hour, and day.
BIIB Economic Scale
Exceeds Bermuda's GDP. Compare with world economies.
BIIB What If Invested
What if you had invested $1,000? See historical returns from any date.
BIIB How It Makes Money
Discover visual breakdown of $9.81B in revenue — where it comes from and where it goes.
BIIB Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
BIIB Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
BIIB Daily Price Character
Explosive · 48.1% historical win rate (green days). Streaks & record days.
BIIB Buybacks
Recent repurchase activity. Shareholder yield & SBC comparison.
BIIB Stock Split History
2 splits on record. Dates, ratios, and cumulative multiple.